Trial Profile
Miltefosine and GM-CSF in Cutaneous Leishmaniasis: a Randomized and Controlled Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Miltefosine (Primary) ; Meglumine antimonate
- Indications Cutaneous leishmaniasis
- Focus Therapeutic Use
- 02 Apr 2020 Status has been changed to completed.
- 20 Jan 2017 New trial record